Related Experiment Videos
[The efficacy of indapamide in different cardiovascular outcome--meta-analysis]
Valentin Brodszky1, Viktor Nagy, Csaba Farsang
1Budapesti Corvinus Egyetem Közszolgálati Tanszék, Egészségügyi-gazdaságtani és Technológiaelemzési Kutatóközpont, Budapest. valentin.brodszky@uni-corvinus.hu
Insights
Indapamide effectively lowers blood pressure and reduces stroke risk, with well-tolerated outcomes. This meta-analysis confirms its efficacy in cardiovascular health for patients requiring antihypertensive treatment.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Context:
- Thiazide diuretics are first-line antihypertensives.
- Previous studies show thiazide efficacy, but a comprehensive indapamide analysis was lacking.
Purpose:
- To conduct a meta-analysis of all randomized controlled trials involving indapamide.
- To assess indapamide's efficacy in cardiovascular and safety outcomes.
Summary:
- Meta-analysis of 9 trials (10,108 patients) showed indapamide prevents stroke (NNT=47.8).
- Indapamide significantly reduced systolic and diastolic blood pressure compared to placebo (7.28/3.50 mmHg).
- Indapamide reduced systolic blood pressure more than active controls (1.30 mmHg) and decreased left ventricular mass index more than enalapril.
Impact:
- Indapamide is effective in stroke prevention and blood pressure reduction.
- Indapamide demonstrates significant benefits in reducing left ventricular mass index.
- Adverse drug reaction rates were similar between indapamide and placebo groups, indicating good tolerability.
Background:
First line antihypertensive treatment's drugs have to be able to decrease the cardiovascular morbidity and mortality. This kind of efficacy of thiazides type diuretics were published earlier in several studies. The efficacy of indapamide was investigated in several studies, but there is no analysis which is including all of the indapamide-studies.
Objective:
We conducted a meta-analysis of all relevant randomized-controlled-trials with indapamide. Efficacy of indapamide was analyzed in different cardiovascular and safety outcomes.
Methods:
We searched the MEDLINE database 1995-2005 for indapamide-trials. Only double-blind, parallel-group design trials were involved. Both the fixed effect model and the random effect model were used for data synthesis, results were probed with Mantel-Hanzel test and inverse variance test.
Results:
Data were combined from 9 trials that included 10 108 patients. Indapamide treatment of 48 patients with a history of stroke prevents another stroke (NNT = 47.8 95% CI 29.6-126.6). Data from 5 trials including 7085 patients show that indapamide is superior to placebo in reducing blood pressure, the differences are: 7.28 mm Hg (95% CI: 6.37-8.19) in systolic blood pressure and 3.50 mm Hg (95% CI 2.99-4.01) in diastolic blood pressure. Data from 5 trials including 2856 patients show that indapamide is superior to active controls in reducing systolic blood pressure, the difference is significant: 1.30 mm Hg (95% CI 0.28-2.31). The difference in diastolic blood pressure was not significant. Data of 505 patients show that indapamide reduced left ventricular mass index significantly more than enalapril 20 mg, the difference is 6.50 g/m(2) (95%CI: 0.81-12.19). Data of 6206 patients show that frequency of adverse drug reaction is similar in the indapamide and placebo groups (rr = 0.97 95%CI 0.76-1.22).
Conclusions:
Indapamide is efficacious in prevention of further stroke, reduces effectively the blood pressure and the left ventricular mass index. Indapamide treatment is well tolerated.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Dose-Response Relationship: Potency and Efficacy
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Heart Failure V: Medical Management
Heart Failure Drugs: β-Blockers